Clinical Trial Update: EffCaMgCit to Prevent Mineral Metabolism and Renal Complications of Chronic PPI Therapy [Phase 3]

View source ↗

Summary

This clinical trial update describes a Phase 3 study of EffCaMgCit aimed at preventing mineral metabolism disturbances and renal complications associated with c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypomagnesemia
• Osteoporosis

Drugs mentioned

• EffCaMgCit

Snippet

Sponsor: University of Texas Southwestern Medical Center | Conditions: Osteoporosis, Hypomagnesemia | Phase 3 | Status: RECRUITING